Cannabiz Australia reports
Helius Therapeutics has had its CBD25 and CBD100 full-spectrum products verified as meeting the quality standard by New Zealand’s Medicinal Cannabis Agency.
Industry sources said the products will be available on prescription in NZ from today. They will eventually be exported around the world, with Europe and South America the priority markets.
Helius is now actively seeking investment to accelerate its domestic and international growth plans.
Chief executive Carmen Doran said: “We have seen significant delays and disruptions in the availability of imported products as Covid continues to impact supply chains.